However, although tumor-suppression has been ascribed to CEACAM1 in a variety of tumors such as mammary, prostate and colonic adenocarcinomas, increased invasion has also been assigned to elevated CEACAM1 expression in some others, including pancreatic, lung (NSCLC) and thyroid adenocarcinomas and melanomas. Here, CEACAM1 is linked to neoplasm.